These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9268007)
1. Modification of natural immunity in mice by imipenem/cilastatin. Ortega E; de Pablo MA; Gallego AM; Alvarez C; Pancorbo PL; Ruiz-Bravo A; de Cienfuegos GA J Antibiot (Tokyo); 1997 Jun; 50(6):502-8. PubMed ID: 9268007 [TBL] [Abstract][Full Text] [Related]
2. Modification of acquired immunity in mice by imipenem/cilastatin. Ortega E; de Pablo MA; Gallego AM; Gaforio JJ; Alvarez C; Ruiz-Bravo A; de Cienfuegos GA J Antimicrob Chemother; 1999 Oct; 44(4):561-4. PubMed ID: 10588322 [TBL] [Abstract][Full Text] [Related]
3. Effects of beta-lactam antibiotics imipenem/cilastatin and cefodizime on cellular and humoral immune responses in BALB/c-mice. Grochla I; Ko HL; Beuth J; Roszkowski K; Roszkowski W; Pulverer G Zentralbl Bakteriol; 1990 Nov; 274(2):250-8. PubMed ID: 2085374 [TBL] [Abstract][Full Text] [Related]
4. In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells. Cornacchione P; Scaringi L; Capodicasa E; Fettucciari K; Rosati E; Sabatini R; Benedetti C; Marconi P; Rossi R; Del Favero A Chemotherapy; 2000; 46(2):135-42. PubMed ID: 10671765 [TBL] [Abstract][Full Text] [Related]
5. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Nakamura T; Hashimoto Y; Kokuryo T; Inui KI Pharm Res; 1998 May; 15(5):734-8. PubMed ID: 9619782 [TBL] [Abstract][Full Text] [Related]
6. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Buckley MM; Brogden RN; Barradell LB; Goa KL Drugs; 1992 Sep; 44(3):408-44. PubMed ID: 1382937 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. Norrby SR; Burman LA; Sassella D; Corigli R; Cassinelli G; Franceschi G; Dornbusch K J Antimicrob Chemother; 1990 Mar; 25(3):371-83. PubMed ID: 2338416 [TBL] [Abstract][Full Text] [Related]
8. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. Nakamura T; Kokuryo T; Hashimoto Y; Inui KI J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324 [TBL] [Abstract][Full Text] [Related]
9. Exposure to imipenem/cilastatin causes nephrotoxicity and even urolithiasis in Wistar rats. Tahri A; Lahyani A; Kallel R; Ayadi F; Boudawara T; Sahnoun Z Toxicology; 2018 Jul; 404-405():59-67. PubMed ID: 29775647 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Ong CT; Kuti JL; Nicolau DP; Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606 [TBL] [Abstract][Full Text] [Related]
14. Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus. Oka S; Goto M; Kaji Y; Kimura S; Matsuda K; Asahi Y; Sanada M; Nakagawa S; Inoue M; Shimada K J Antimicrob Chemother; 1993 Apr; 31(4):533-41. PubMed ID: 8514648 [TBL] [Abstract][Full Text] [Related]
15. Imipenem/cilastatin sodium in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. Lui SF; Cheng AB; Leung CB; Wong KC; Li PK; Lai KN Am J Nephrol; 1994; 14(3):182-6. PubMed ID: 7977477 [TBL] [Abstract][Full Text] [Related]
16. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273 [TBL] [Abstract][Full Text] [Related]
17. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations. Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166 [TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa-acquired resistance to imipenem-cilastatin: commentary on clinical implications of antibiotic resistance. Tidwell BH; Cleary JD Pharmacotherapy; 1993; 13(2):165; discussion 166. PubMed ID: 8469624 [No Abstract] [Full Text] [Related]
20. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice. Brook I J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]